Ascendis Pharma A/S (ASND)
256.82
+3.37
(+1.33%)
USD |
NASDAQ |
Nov 06, 16:00
256.78
-0.04
(-0.02%)
After-Hours: 20:00
Ascendis Pharma Total Long Term Debt (Quarterly) : 439.76M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 439.76M |
| March 31, 2026 | 961.26M |
| December 31, 2025 | 956.76M |
| September 30, 2025 | 890.19M |
| June 30, 2025 | 878.34M |
| March 31, 2025 | 871.59M |
| December 31, 2024 | 852.51M |
| September 30, 2024 | 849.31M |
| June 30, 2024 | 697.97M |
| March 31, 2024 | 706.98M |
| December 31, 2023 | 699.29M |
| September 30, 2023 | 692.44M |
| June 30, 2023 | 523.00M |
| March 31, 2023 | 521.48M |
| December 31, 2022 | 542.57M |
| September 30, 2022 | 522.30M |
| June 30, 2022 | 520.77M |
| March 31, 2022 | 517.09M |
| December 31, 2021 | 119.36M |
| September 30, 2021 | 118.56M |
| June 30, 2021 | 119.79M |
| March 31, 2021 | 113.39M |
| December 31, 2020 | 112.54M |
| September 30, 2020 | 39.03M |
| June 30, 2020 | 39.85M |
| Date | Value |
|---|---|
| March 31, 2020 | 40.67M |
| December 31, 2019 | 41.10M |
| September 30, 2019 | 40.26M |
| June 30, 2019 | 41.34M |
| March 31, 2019 | 19.63M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 4.174B |
| Novo Nordisk A/S | 17.89B |
| Genmab A/S | 4.880B |
| Zealand Pharma A/S | 62.86M |
| Evaxion AS | 7.105M |